Emerging at the UK, retatrutide, a new peptide , is creating considerable interest within the scientific community regarding its promise for body regulation. This dual GIP and GLP-1 receptor agonist looks to offer a considerable improvement over established therapies, showing positive results in initial clinical studies . Researchers suggest its di